These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 9586913

  • 21. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL, Rudd R, Ruiz de Elvira MC, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C.
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [Abstract] [Full Text] [Related]

  • 22. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA, Herndon JE, Hollis DR, Ellerton J, Langleben A, Richards F, Green MR.
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [Abstract] [Full Text] [Related]

  • 23. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 24. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, Lee JS.
    J Clin Oncol; 2005 May 20; 23(15):3488-94. PubMed ID: 15908658
    [Abstract] [Full Text] [Related]

  • 25. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 20; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 26. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 20; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 27. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2007 Jun 20; 60(1):1-6. PubMed ID: 17393168
    [Abstract] [Full Text] [Related]

  • 28. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun 20; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA, Bacchi M, Hürny C, Bernhard J, Cerny T, Martinelli G, Leyvraz S, Senn HJ, Stahel R, Siegenthaler P.
    Ann Oncol; 1995 Feb 20; 6(2):157-66. PubMed ID: 7786823
    [Abstract] [Full Text] [Related]

  • 32. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):807-11. PubMed ID: 7860392
    [Abstract] [Full Text] [Related]

  • 33. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T, Fukuoka M, Negoro S, Sugiura T, Kawahara M, Kudoh S, Araki J, Nakagawa K, Yokozaki M, Yamakido M, Ariyoshi Y.
    Gan To Kagaku Ryoho; 2000 Jul 15; 27(8):1091-6. PubMed ID: 10945001
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
    Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO.
    J Clin Oncol; 1992 Feb 15; 10(2):282-91. PubMed ID: 1310103
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A, Crosby L, Remick SC, Makkar V, Levitan N.
    Lung Cancer; 2001 May 15; 32(2):155-62. PubMed ID: 11325486
    [Abstract] [Full Text] [Related]

  • 39. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.
    Jpn J Clin Oncol; 1994 Oct 15; 24(5):275-81. PubMed ID: 7967106
    [Abstract] [Full Text] [Related]

  • 40. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ, Movsas B, Byhardt RW, Radiation Therapy Oncology Group 9609.
    J Clin Oncol; 2005 Aug 01; 23(22):4991-8. PubMed ID: 15939930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.